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Breast cancer is the most common female cancer. Worldwide, more than a million women are diagnosed
every year. However despite this increase, the mortality rate is declining. This is due to combination of
factors including early diagnosis and effective treatment. This manuscript which is presented in two
sections outlines the current status in management of early breast cancer. Section 1 focuses on the
advances in diagnosis and surgical treatment of breast cancer and give an overview of the histopatho-
logical aspects. The focus of section 2 is on advances on adjuvant treatment of breast cancer including
radiotherapy, chemotherapy and endocrine treatment.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Breast cancer is the most common female cancer. Worldwide,
more than amillionwomen are diagnosed every year. In 2005more
than 45,500 women were diagnosed in the UK with breast cancer.
In the last ten years, female breast cancer incidence rate in the UK
have increased by 13%, however despite this increase, the mortality
rate is declining (Fig. 1). There were 12,082 deaths from breast
cancer; 11,990 (99%) of these were in women and 92 (1%) were in
men.1e3
Multidisciplinary team (MDT) approach in management of
breast cancer patients, joint clinics and weekly MDT meetings for
diagnosis and treatment planning, remain central to the
management and is regarded as one of the major advances in this
ﬁeld. It has led to tailoring therapy to the individual patients'
needs with the involvement of all members of the team.tment of Surgery, Royal Free
, UK. Tel.: þ44 20 76799214;
r).
ciates Ltd. Published by Elsevier Lt2. Breast cancer diagnosis
Diagnosis of breast cancer is carried out by triple assessment
which includes clinical evaluation, breast imaging and tissue
diagnosis (cytological or histological assessment).
Full-ﬁeld digital mammography has allowed more conﬁdent
identiﬁcation and characterisation of microcalciﬁcations, particu-
larly in dense breast tissue. Digital equipment, although more
expensive than analogue units, provides a major advantage in
stereotactic procedures for impalpable lesions including guide wire
placement, core biopsy and vacuum-assisted excision where small
lesions can be completely removed percutaneously using a mam-
motome. Advances in the sensitivity of breast imaging and the
extension of mammographic screening programmes in Europe and
North America have undoubtedly contributed to the reported rising
incidence of breast cancer, and the current controversy
surrounding overdiagnosis of clinically unimportant lesions with
potentially harmful overtreatment in some women.4
Breast magnetic resonance imaging (MRI) has become awidely-
used second-line imaging modality with well-deﬁned roles in
assessing tumour multifocality and planning surgery5 and ind. All rights reserved.
Fig. 1. Declining breast cancer mortality in the UK. (http://info.cancerresearchuk.org/cancerstats/types/breast/mortality/).
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MRI screening is advised in high-risk young women such as those
with a BRCA gene mutation or with previous mantle irradiation for
lymphoma, and in assessing gel implants for leak or rupture.3. Advances in surgical treatment
Over the last 30 years themajor change in the surgical treatment
of early breast cancer has been the shift towards breast conserva-
tion treatment. Breast conserving surgery (BCS) was introduced to
reduce the physical and psychological consequences of removing
the whole breast. Trials performed in the 1970s demonstrated
equivalent survival when comparing BCS and radiotherapy with
mastectomy.6 Local recurrence rates were higher in the BCS and
radiotherapy group. However patients developing local recurrence
were salvaged by a mastectomy. Radiotherapy is now accepted as
standard treatment for patients with early breast cancer under-
going BCS.
The meta-analysis conducted by the Early Breast Cancer Tri-
alist's Collaborative Group comparing BCS with BCS and radio-
therapy demonstrated that the addition of radiotherapy reduced
the risk of local recurrence by 75% and resulted in a disease free
survival advantage, with a decrease in the 15 year risk of dying of
breast cancer from 31% to 26% in node negative patients and
55e48% in node positive patients.7,8
Between 1980 and 2004, the mastectomy rate at theMayo Clinic
fell from 91% to 36%.9 Currently in the UK about two-thirds of newly
diagnosed cancers are amenable to breast conservation (wide local
excision and radiotherapy) but in the remaining third, mastectomy
is still undertaken because of tumour size, location within the
central breast, tumour multicentricity, or patient preference.
For patients undergoing breast conservation, breast surgeons
trained in newer oncoplastic procedures can achieve better
outcomes with regard to long-term cosmesis. Glanduloplasty
techniques using local breast tissue ﬂaps reduce the cavity left in
the tumour bed and allow wide tissue margins around the tumour
to be resected so that cancer clearance is not compromised.
In patients with large breasts, therapeutic mammoplasty can
achieve better cosmetic outcomes and maintain breast symmetry.
Here the tumour and surrounding margins are excised widely as
part of a reduction mammoplasty, with the design of the nipple-
areolar pedicle tailored to the area of tumour excision. Contra
lateral breast reduction can be undertaken at the same time or at
a later date. For the surgical team there is inevitably a considerable
increase in requirements for operating theatre time with more
complex oncoplastic surgery.BCS aims to achieve good local control of both the primary
tumour and regional nodes, and attention to histological clearance
of margins is essential to ensure complete tumour excision. Local
recurrence rates following BCS are the prime quality indicator for
adequacy of surgery and the recommended minimum standard,
and targets for local recurrence after BCS have now been revised to
a maximum of 5% at 5 years and a target of <3% at 5 years.104. Advances in mastectomy and breast reconstruction
The technique of mastectomy has evolved steadily over the last
50 years with abandonment of the radical Halsted mastectomy in
favour, initially of a modiﬁed procedure sparing the pectoral
muscles, and more recently adopting skin-sparing techniques,
where only the skin of the nippleeareola complex is included in the
resection, to allow the uninvolved skin envelope to be conserved
for breast reconstruction. Endoscopic breast surgery is an emerging
technique which aims to reduce still further the extent of scarring
on the breast, and is currently being undertaken in the context of
clinical trials.11
UK and European guidelines for breast cancer treatment
recommend that reconstruction should be available to women
requiring mastectomy.5 Immediate reconstruction can make the
prospect of mastectomy easier to bear in some women, but not all
patients will be suitable for immediate reconstruction. Some
women may decline because of personal preference12 and some
women will be advised against immediate reconstruction for
oncological reasons. The expanded indications for post-mastec-
tomy radiotherapy (see Section 2 of this paper) has resulted in
a move away from immediate reconstruction in patients with large
or high-grade tumours or where lymphovascular invasion or nodal
involvement predict the likely recommendation of chest wall
radiation.
The concerns previously raised on the use of silicone gel
implants have largely been dispelled13 and implants are considered
safe and effective components of the reconstructive armamen-
tarium. Advances in gel cross-linking have reduced silicone “bleed”
and cohesive gel implants are likely to experience fewer problems
with late extracapsular rupture. Myocutaneous ﬂaps using the
latissimus dorsi (LD) muscle from the back or lower abdominal
tissue based on the deep inferior epigastric perforators (DIEP ﬂap)
can replace relatively large volumes of breast tissue, either alone or
in combinationwith implants, and are used both for immediate and
delayed reconstruction. The LD ﬂap is a robust reconstructive
technique and is within the current training repertoire of most
breast surgeons. The free DIEP ﬂap technique requires
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ating theatre time and is usually undertaken by the plastic surgical
team.
5. Risk-reducing breast surgery
Risk-reducing (prophylactic) mastectomy and reconstruction is
available for women at very high-risk, such as patients with
previous breast cancer or women carrying a BRCA gene mutation.14
Counselling and psychological assessment of women with an
increased genetic predisposition is mandatory and the availability
of immediate reconstruction is particularly important to themental
health of this group of patients and is the preferred option.15
Currently the most frequent clinical setting for risk-reducing
mastectomy is in the contra lateral breast following unilateral
breast cancer diagnosis. Young women in particular with a breast
cancer diagnosis are increasingly opting for risk-reducing contra
lateral mastectomy, both with invasive disease and in situ carci-
noma, with reported increases from 2.1% to 5.2% overall (i.e.
including patients suitable for breast conservation) and from 6.4%
to 18.4% in those requiring mastectomy for treatment.16
6. Advances in regional nodal staging
Despite advances in genetic subtyping of tumours and
increasingly sophisticated receptor analysis in breast cancers, the
axillary lymph node status remains the strongest predictor of
long-term prognosis in invasive disease.17 Sentinel lymph node
biopsy (SLNB) rather than full nodal clearance is accepted as the
standard of care for axillary staging in early breast cancer, deliv-
ering less morbidity in terms of shoulder stiffness and risk of
lymphoedema and offering a signiﬁcantly reduced hospital
stay.17e22 Some centres are now offering upfront SLNB under local
anaesthesia a week prior to deﬁnitive breast cancer surgery23
however intra-operative diagnosis of sentinel lymph node is the
way forward.24
Quality assurance and training of surgeons, pathologists and
nuclear medicine physicians has been undertaken in breast units
across the UK25 and techniques have been standardised to ensure
that SLNB avoids the pitfall of understaging axillary involvement
(false negative SLNB) with consequent undertreatment. The
double-dye localization technique, incorporating both radionu-
clide and Patent V blue dye injection, is regarded as superior to
single-dye techniques. Frozen section reporting and imprint
cytology of SLNB are used in some centres to enable further
axillary surgery, where indicated, to proceed under the same
anaesthetic. Currently trials are in progress to assess whether
SLNB analysis with gene ampliﬁcation can replace conventional
histopathology.26 The aim is to determine whether reliable and
rapid intra-operative diagnosis can avoid readmission and second
operations in patients with positive SLNB.26 Currently there is
controversy about the signiﬁcance of detection of isolated tumour
cells within the sentinel lymph node. With advances in gene
analysis and proﬁling there may be no need for nodal surgery for
staging purposes in future.
7. Histopathology of breast cancer
All breast cancers are adenocarcinomas arising from the
terminal duct lobular units. Breast cancers are divided into two
main categories, non invasive and invasive. Inﬁltrating ductal
carcinoma is the most common breast cancer histology, accounting
for about 80% of all breast cancers. Lobular carcinoma constitutes
10% of the breast cancers.8. Non invasive breast cancer
Ductal carcinoma in situ (DCIS) is the most common type of non
invasive breast cancer, accounting for about 15% of all newly
diagnosed breast cancer cases. DCIS refers to an uncontrolled
proliferation of cells that are conﬁned to the breast duct so the
basement membrane of the breast dusts remains intact. Eventually,
the cells outstrip their blood supply and become necrotic centrally.
This debris can calcify and be detected mammographically. DCIS is
classiﬁed into ﬁve histological subtypes associated with varying
prognostic implications. Recognized patterns include: solid, papil-
lary, cribriform, micropapillary and comedo. Most lesions represent
a combination of at least two of these subtypes. Comedo carcinoma
is considered high-grade and predictive of recurrence. In patients
with DCIS the invasive cancer usually occurs within the same
breast, however women with DCIS are also at a higher risk of
developing cancer in the contra lateral breast.27
Lobular carcinoma in situ (LCIS) is characterized as a benign-
appearing proliferation of terminal ducts and ductules that is often
multifocal and bilateral. LCIS is much less common and is associ-
ated with less risk of the development of invasive cancer than DCIS.
LCIS is considered a marker that identiﬁes women at increased risk
of invasive breast cancer; it is typically multifocal and is frequently
bilateral.
9. Invasive breast cancer
Invasive ductal carcinoma (IDC) is the most common type of
breast cancer. About 80% of invasive breast cancers are classiﬁed as
invasive ductal carcinoma. The tumour cells have penetrated the
ductal basement membrane and inﬁltrates into the surrounding
breast tissue. The invasive tumour is characterized by tumour cells
arranged in cords, islands, and glands embedded in a dense ﬁbrous
stroma. The tumour cells have the potential to metastasize to other
parts of the body through the bloodstream or lymphatic system.
Most IDC's have no speciﬁc histological characteristics and are
classiﬁed as No Special Type (NST).27,28
Invasive lobular carcinoma (ILC) originates in the lobules where
it extends into the surrounding breast parenchyma. It is less
common than IDC, accounting for about 10% of invasive breast
cancers and has a tendency to be multifocal. Tumour cells are often
arranged in single ﬁles/strands, but at times it may be difﬁcult to
distinguish from ductal carcinomas. Immunohistochemistry stain-
ing for E-Cadherin is helpful in differentiating ILC from IDC, ILC
loses E-cadherin expression.27
9.1. Other histological types of breast cancer
Tubular carcinoma is a highly differentiated invasive carcinoma
with limited metastatic potential and better than average prog-
nosis. Medullary carcinoma is a relatively uncommon type of
Invasive carcinoma, accounting for less than 5e7% of all invasive
breast cancers. Mucinous carcinoma is an invasive form of breast
cancer characterized by large amounts of extracellular mucin
production and is associated with a relatively favorable prognosis.
Invasive cribriform carcinoma is a well-differentiated cancer which
shares some features with tubular carcinoma and is also associated
with better than average prognosis. Adenoid cystic carcinomas
similarly rarely spread to the lymph nodes or distant areas, and
have a very good prognosis.
Pagets disease is a subtype in which malignant ductal cells
extend intraepithelially into the epidermis of the nipple. The Paget
cells, characteristic large cells surrounded by a clear halo-like area,
invade the epidermis; underlying ductal carcinoma is almost
always present. It accounts for approximately 1% of all breast
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than 1e2% of invasive breast cancers. Invasive micropapillary
carcinoma is a distinct but poorly recognized variant with an
incidence of less than 3% but is associated with a relatively poor
prognosis with frequent skin invasion and extensive nodal
involvement.
Inﬂammatory breast cancer is relatively rare, representing about
1e5% of all breast cancers. Lymphatic involvement of skin by
underlying carcinoma, causing red, swollen, hot skin resembling an
inﬂammatory process; peau d'orange and is associated with poor
prognosis.
10. Basal type breast cancer
Basal type breast cancer was ﬁrst described in 2003. The breast
cancer cells have particular genetic changes. The p53 gene is
damaged (mutated) or lost. The cells make large amounts of
a protein called cytokeratin 5/6. Basal type breast cancers are often
triple negativee meaning that they don't have many receptors for
oestrogen, progesterone or Herceptin (HER). BRCA1/2-related
breast cancers are more likely than non-BRCA1/2-related breast
cancer to express a basal epithelial phenotype.29,30
11. Receptors
In current clinical practice, Oestrogen (ER), Progesterone (PR)
and Her 2 testing is mandatory in all newly diagnosed breast
cancers, and accurate results are critical in determining the use of
adjuvant hormonal therapy. Immunohistochemistry is the method
of choice to detect the nuclear steroid receptors in tumour cells and
the membrane staining for HER2. Approximately 75% of breast
cancers are hormone receptor positive and 15e25% are HER2
positive. The Hormone receptors are assessed using the Allred or
Quick score where numerical scores are given to the percentage of
nuclei containing the hormone and the intensity of staining up to
a maximum of 8.
HER2 score is dependent on the percentage of cells staining and
the intensity and completeness of membrane staining. A score of
3þ is deemed positive and patients qualify for Herceptin treatment.
A score of 2þ is borderline and the tumour must be tested for gene
ampliﬁcation using Fluorescent in situ Hybridization (FISH).
Around 15e20% of all breast cancers do not have hormone or HER2
receptors. Sometimes referred to as ‘triple negative’ breast cancer,
these are typically more aggressive and difﬁcult to treat. Breast
cancer cells that overexpress HER2 are thought to have four to ﬁve
time as many cancer stem cells compared with HER2 negative
breast cancer cells.31,32
12. Adjuvant treatment of breast cancer
In addition to surgery, there are other treatment modalities for
the management of breast cancer patients. These include radio-
therapy, chemotherapy and endocrine therapy which are discussed
in section 2 of this article.
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